Don't Be Surprised to Dispense Baricitinib for COVID-19

The oral rheumatoid arthritis med baricitinib (Olumiant) is now authorized to treat COVID-19 in hospitalized patients.

Baricitinib is a Janus kinase (JAK) inhibitor that helps reduce inflammation...and it may have antiviral effects.

Adding it to remdesivir (Veklury) for certain COVID-19 patients may reduce recovery time by one day...compared to remdesivir alone.

Get unlimited access through an Enterprise license

Hospital Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals